Join to View Full Profile
3911 Avenue BSuite 1100Scottsbluff, NE 69361
Phone+1 308-630-2101
Fax+1 316-262-0706
Dr. Johnson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1983 - 1986- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1980 - 1983
University of Colorado School of Medicine Anschutz Medical CampusClass of 1980
Certifications & Licensure
KS State Medical License 1988 - 2025
WY State Medical License 1985 - 2025
NE State Medical License 2013 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-...Roberto A. Leon-Ferre, Edith A. Perez, David W. Hillman, Celyne Bueno, Alejandra T. Perez
Breast Cancer Research and Treatment. 2020-08-01 - 103 citationsComprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-...Erica Hlavin Bell, Peixin Zhang, Edward G. Shaw, Jan C. Buckner, Geoffrey R. Barger
Journal of Clinical Oncology. 2020-07-24 - 8 citations"Enjoy glass of wine before eating:" a randomized trial to test the orexigenic effects of this advice in advanced cancer patients.Aminah Jatoi, Rui Qin, Daniel Satele, Shaker R. Dakhil, Pankaj Kumar
Supportive Care in Cancer. 2016-04-02
Press Mentions
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to Anti-PD-L1 TherapiesMay 25th, 2021- Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and DerivativesMay 24th, 2021
- Enveric Biosciences Buys MagicMed in All Stock Deal Valued at $30 MillionMay 24th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
